Company: IOBT
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047744
Chunk: 49

Company: IO Biotech, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 49
---
41 days. A separate granted patent in the United States application covers nucleotides encoding IO102 and will expire April 17, 2029 (no patent term adjustment). A separate pending United States application covers methods of treatment using nucleotides encoding IO102. A separate pending United States application has recently been filed with a view to covering vectors comprising multiple copies of a nucleotide encoding IO102.  In other jurisdictions it is not typically necessary to present claims to compositions of matter separately from methods of treatment and thus both types of claim appear in the same patent. The family includes granted patents in Europe, Hong Kong, China, Japan, Canada, Australia, Israel, New Zealand and South Africa, each of which has claims covering IO102 as a compositions of matter and the local equivalent of methods of treatment using IO102. Each of these patents has the normal 20 year term expiring April 17, 2029. The family also includes a pending application in Europe; 

42

•Family 2 is based on a PCT application filed March 3, 2017.  Patents granted from this family will expire March 3, 2037 based on a normal 20 year term. Granted patents in Europe and Japan cover the combination of IO102, IO103 and an anti-PD1 antibody for use in a method for preventing or treating cancer. Separate pending applications in Europe, Hong Kong and Japan cover administration of IO102 + anti-PD-1 antibody in separate compositions to IO103. The family also includes a pending application in the United States with claims covering a method of treating a PD-L1 expressing cancer by administering IO103 + anti-PD1 antibody and an adjuvant;

•Family 3 is based on a PCT application filed April 23, 2018.  Patents granted from this family will expire April 23, 2038 based on a normal 20 year term. The family includes pending applications in the United States, Europe, Japan and China. Claims are directed to combined uses of IO102, IO103 and a specific category of therapeutic antibody, i.e. those which operate via antibody-dependent cellular cytotoxicity (“ADCC”) mechanisms of action;  

•Family 13 is based on a PCT application filed August 31, 2021. Patents granted from this family will expire August 31, 2041 based on a normal 20 year term. The family includes pending applications in the United States, Europe, China, Japan, Republic of Korea